Jennifer Shoskes
Fulcrum Therapeutics (United States)(US)
Publications by Year
Research Areas
Muscle Physiology and Disorders, Ubiquitin and proteasome pathways, Genetic Neurodegenerative Diseases, Melanoma and MAPK Pathways, interferon and immune responses
Most-Cited Works
- → Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial(2024)31 cited
- → 461P Evaluation of PGN-EDODM1: FREEDOM-DM1 and FREEDOM2-DM1 clinical trials in myotonic dystrophy type 1(2024)2 cited
- → Design of REACH: Phase 3 Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of the Efficacy and Safety of Losmapimod in FSHD (P6-8.007)(2023)2 cited
- → An Open-Label Study of Losmapimod to Evaluate the Safety, Tolerability, and Biomarker and Clinical Outcome Assessment Changes in Subjects with FSHD1 (S23.008)(2022)1 cited
- → Results from 96 Weeks Open-Label Extension of a Phase 2 Trial of Losmapimod in Subjects with FSHD: ReDUX4 (S48.008)(2023)1 cited
- → Positive results from a first-in-human study supporting continued development of PGN-EDO51 for the treatment of duchenne muscular dystrophy (DMD)(2023)1 cited
- → Muscle Ultrasound in an Open-Label Study of Losmapimod in Subjects with FSHD1 (P5-8.011)(2023)
- → Reachable Workspace to Evaluate Efficacy of Losmapimod in Subjects with FSHD in Two Phase 2 Studies (P4-13.008)(2022)
- → P.135 Safety and tolerability of losmapimod for the treatment of FSHD(2022)
- → Feasibility of Measuring Functional Performance of FSHD Patients Using Wearable Sensors to Quantify Physical Activity (S7.006)(2023)